IP Library Granted Patent US 11,059,889
Granted Patent B2
US 11,059,889 · App. 16/392,418 · Granted Jul 13, 2021

Anti-human Igβ antibody

Inventors: Daisuke Yamajuku (Tokyo, JP); Mutsumi Seki (Tokyo, JP); Takashi Honda (Tokyo, JP); Satoshi Kubo (Tokyo, JP); Shinji Soga (Tokyo, JP); Akifumi Morinaka (Tokyo, JP)
Assignee: Astellas Pharma Inc.
C07K16/2803A61K39/395C07K16/28C07K16/46C12N5/10C12N15/02C12N15/09C07K2317/24C07K2317/33C07K2317/52C07K2317/56C07K2317/565C07K2317/92
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,059,889
App. No.
16/392,418
Granted
Jul 13, 2021
Kind
B2
Abstract

Described herein are novel anti-human Igβ antibodies, as well as methods for making the antibodies and using the antibodies to treat or prevent autoimmune disease.

Claims (5)

1. A polynucleotide encoding a heavy chain of an anti-human Igβ antibody of any one of the following (a) to (c); or encoding a light chain of an anti-human Igβ antibody of any one of the following (a) to (c):

(a) an anti-human Igβ antibody comprising a heavy chain and a light chain, wherein the heavy chain comprises a heavy chain variable region consisting of the amino acid sequence of amino acid numbers 1 to 119 of SEQ ID NO: 6 and a heavy chain constant region which is a human Igγ1 constant region having amino acid mutations of S239D, H268D, and L328W, and the light chain comprises a light chain variable region consisting of the amino acid sequence of amino acid numbers 1 to 112 of SEQ ID NO: 8;

(b) an anti-human Igβ antibody comprising a heavy chain and a light chain, wherein the heavy chain comprises a heavy chain variable region consisting of the amino acid sequence of amino acid numbers 1 to 119 of SEQ ID NO: 2 and a heavy chain constant region which is a human Igγ1 constant region having amino acid mutations of S239D, H268D, and L328W, and the light chain comprises a light chain variable region consisting of the amino acid sequence of amino acid numbers 1 to 112 of SEQ ID NO: 4;

(c) an anti-human Igβ antibody comprising a heavy chain and a light chain, wherein the heavy chain comprises a heavy chain variable region consisting of the amino acid sequence of amino acid numbers 1 to 119 of SEQ ID NO: 10 and a heavy chain constant region which is a human Igγ1 constant region having amino acid mutations of S239D, H268D, and L328W, and the light chain comprises a light chain variable region consisting of the amino acid sequence of amino acid numbers 1 to 112 of SEQ ID NO: 12.

2. An expression vector comprising the polynucleotide of claim 1 .

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 29, 2024
From: ASTELLAS PHARMA INC.
To: MACH5 THERAPEUTICS, INC.
Reel/Frame 067546/0530 →
Priority Claims (1)
JP 2014-160141 · Aug 6, 2014 · national
Continuity (2)
Continuation 15501626
Related Publication 20190309063A1 · Oct 10, 2019